Special Issue "CAR-T Cell Therapy"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (30 November 2019).
Interests: cancer metastasis; cancer drug resistance; epigenetics; non-coding RNAs; miRNAs; breast cancer; prostate cancer; lung cancer; meningioma; pancreatic cancer; cancer health disparity
Special Issues and Collections in MDPI journals
Special Issue in Cancers: Cancer Drug Resistance: An Epigenetic Approach
Special Issue in International Journal of Molecular Sciences: CAR-T Cell Therapy 2.0
CAR (Chimeric Antigen Receptor) T-cell therapy is revolutionizing cancer treatment. Several monoclonal antibody-based immunotherapies are available to treat various cancers, but CAR T-cell therapy belongs to the class of ‘adoptive cell transfer’ therapy that makes use of a patient’s own T-cells to fight back against cancer. It involves the harvesting of T-cells and their genetic modification to express an antigen receptor that is normally not present. This creates a chimeric molecule—a T-cell with the combined specificity of an antibody. The receptor chosen to create a CAR T-cell depends on the cancer in question and the identification of a surface protein that is unique to the cancer cells, so that CAR T-cells, once introduced back into the patient, can specifically target and kill cancer cells. This therapy is particularly effective against liquid malignancies with the recent FDA approval of drugs against leukemia and non-Hodgkin lymphoma. The solid tumors, with their protective microenvironment, are a challenge to be targeted by CAR T-cells. Additionally, certain toxicities, primarily neurological complications and cytokine release syndrome, have been associated with this therapy. Finally, attempts are being made to find the utility of CAR T-cell therapy in diseases other than cancer. This Special Issue takes a look at the CAR T-cell therapy—its evolution, progress, and promises, as well as its associated challenges.
Dr. Aamir Ahmad
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Chimeric Antigen Receptor
- T lymphocyte
- CAR T-cell therapy
- adoptive cell transfer therapy
- Cytokine Release Syndrome